Pemetrexed for the treatment of non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Pemetrexed for the treatment of non-small-cell lung cancer.

Pemetrexed for the treatment of non-small-cell lung cancer.

http://www.wikidata.org/entity/Q35003631

about

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.

P2860

Q52633236-FC18D35C-C348-4F34-AFB1-7D0D3587F1F2

P2860

Pemetrexed for the treatment of non-small-cell lung cancer.

http://www.wikidata.org/entity/Q35003631

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Pemetrexed for the treatment of non-small-cell lung cancer.

@ast

Pemetrexed for the treatment of non-small-cell lung cancer.

@en

type

label

Pemetrexed for the treatment of non-small-cell lung cancer.

@ast

Pemetrexed for the treatment of non-small-cell lung cancer.

@en

prefLabel

Pemetrexed for the treatment of non-small-cell lung cancer.

@ast

Pemetrexed for the treatment of non-small-cell lung cancer.

@en

P1433

Q35003631-DD090EA1-0415-455F-B3EF-910449562290

P1476

Q35003631-76F679FC-B7B0-4E1B-B0B9-5EB550C16167

P2093

Q35003631-194D31FA-9205-4250-A627-C9BC6C5BB155

Q35003631-1E9F7ADF-4729-446E-94BA-7DAEC58962A3

Q35003631-B8D85A09-E038-4620-9E6A-A48C9E3BA683

P2860

Q35003631-033270B4-B32C-430F-BCDA-35893BF820CF

Q35003631-0E0E33B9-D096-492E-A57D-DE2D871BB189

Q35003631-14DEA13E-B0A3-4633-A5E9-629B274086A6

Q35003631-150ADF07-E5DE-42D7-8743-A02092F5B550

Q35003631-19BCE75D-426D-4720-9B33-6D5BD74F9788

Q35003631-1B37BA45-FEC2-4865-BE7B-B663418CD27C

Q35003631-1DF86F48-5C34-4EB7-97D0-41EB4BEDFB92

Q35003631-21D7765E-B7AC-46A3-BBAB-CA9C7B2023D2

Q35003631-21E798A7-9029-498E-9B32-C38AA8F6E6F5

Q35003631-24A38652-AA1D-4437-9C76-41FA508B665F

P304

Q35003631-6A49E943-2027-4632-8B05-138D45C159F8

P31

Q35003631-A1735126-1822-4122-8081-4D28869F861D

P356

Q35003631-0235310F-B50B-4608-9EB1-38F4FA4FD14C

P433

Q35003631-6B83C16C-2215-4D3C-92D9-BA56EF580168

P478

Q35003631-4E435001-34C8-40C2-B04F-533C4D6ACF8C

P577

Q35003631-B7B158B5-6134-4D63-8A9A-01541D5AE47A

P698

Q35003631-9AA7C9E0-F535-4427-B13D-61C9A1BF63CF

P356

P1433

Expert Review of Anticancer Therapy

P1476

Pemetrexed for the treatment of non-small-cell lung cancer.

@en

P2093

Christian Manegold

http://www.w3.org/2001/XMLSchema#string

Gerald Schmid-Bindert

http://www.w3.org/2001/XMLSchema#string

Lothar R Pilz

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.

P304

1195-1209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.09.97

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19761423

http://www.w3.org/2001/XMLSchema#string